ArticleEuropean journal of medical research2025
LIG1 overexpression enhances DNA repair and immune escape leading to poor prognosis in osteosarcoma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OS), the most common primary malignant bone tumor in adolescents, exhibits high metastasis and poor response to current therapies. DNA Ligase I (LIG1), a key enzyme in DNA replication and repair, has been implicated in multiple cancers, but its role in OS remains unclear.
methodsTranscriptomic and clinical data from the TCGA-OS cohort were analyzed to assess LIG1 expression, immune infiltration, and prognosis. Functional studies using gain- and loss-of-function assays evaluated its impact on OS cell viability, clonogenicity, and apoptosis. The effects of LIG1 inhibition by epigallocatechin gallate (EGCG) were also examined.
resultsLIG1 was significantly upregulated in OS tissues and correlated with reduced overall and disease-free survival. High LIG1 expression was linked to an immunosuppressive microenvironment with fewer cytotoxic T cells and increased Tregs and M2 macrophages. Functionally, LIG1 promoted OS cell proliferation and survival, while its inhibition by EGCG suppressed tumor growth.
conclusionsLIG1 drives OS progression and immune evasion by remodeling the tumor microenvironment. It serves as an independent prognostic biomarker and a potential therapeutic target, particularly in combination with immune checkpoint blockade.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.